Prevent IDIQ mato RFP
Closed Solicitation Posted
This opportunity was awarded. See its 11 award notices in the notice history.
- Solicitation number
- 75N91023R00024
- Agency
- National Cancer Institute National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- Richard Taylor rich.taylor@nih.gov (717) 339-9735
Notice details come from SAM.gov. Updated .
About this opportunity
The National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, is seeking proposals for the PREVENT Cancer Preclinical Drug Development Program. This program includes preclinical efficacy and biomarker testing, as well as preclinical services for biopharmaceutical product development, manufacturing, toxicology, and pharmacology. The solicitation, 75N91023R00024, has a due date of February 28, 2023, and potential offerors may submit questions until January 31, 2023. Proposals will be evaluated based on technical approach, management approach, and cost.
This is an unrestricted procurement with no set-asides. There is no information provided about potential incumbent contractors or award values. The work is classified under NAICS code 541714 for Research and Development in Biotechnology and PSC code AN12 for Health R&D Services. The place of performance is not specified, but the services required indicate this will likely be conducted at the contractor's facility.
Notice text
3 versions
Update #3 · Latest ·
Amendment 02 is to issue minor changes to solicitation, 75N91023R00024, for the PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing. See attached for additional details.
Update #2 ·
Amendment 01 Q&A for solicitation, 75N91023R00024, is for the PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing. See attached for additional details.
Update #1 ·
This solicitation, 75N91023R00024, is for the PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing. See attached for additional details.
Attachments
| File | Type | Posted |
|---|---|---|
| Attachment_10thru14_REVISED_0002.pdf | ||
| Amendment_2_75N91023R00024_RFP_0002.pdf | ||
| RFP_PREVENT_75N91023R00024_Amend02_no_DMS_0002.pdf | ||
| Sol_75N91023R00024_Amd_0002.pdf | ||
| Questions__Answers_PREVENT_23R00024Amend1_0001.pdf | ||
| Sol_75N91023R00024_Amd_0001.pdf | ||
| Attachment_18_Breakdown_of_Proposed_Estimated_Costs_Spreadsheet.xlsx | XLSX spreadsheet | |
| Attachment_19thru23.pdf | ||
| Attachment_16_17.pdf | ||
| Attachment_10thru14.pdf | ||
| RFP_PREVENT_75N91023R00024.pdf | ||
| Attachment_24thru28.pdf | ||
| Attachment_1_2.pdf | ||
| Attachment_3thru9.pdf |
Show all 14
Notice history
| Notice | Type | Posted |
|---|---|---|
| PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing | Award Notice | |
| PREVENT Preclinical Efficacy & Endpoint Biomarkers | Award Notice | |
| PREVENT Preclinical Efficacy & Endpoint Biomarkers | Award Notice | |
| Prevent IDIQ mato RFP | Solicitation | |
| Prevent IDIQ mato RFP | Pre-Solicitation |
And 8 more award notices.
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity